Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Vutrisiran Attenuates Worsening in LA Strain in Patients With ATTR-CMIn patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), vutrisiran attenuated worsening in left atrial (LA) strain at 30 months, according to a secondary analysis of the HELIOS-B trial recently published in JAMA Cardiology.
- Advocacy in Sports Cardiology: From Sidelines to StatehousesAdvocacy has become an increasingly important component of sports cardiology. As public attention surrounding sudden cardiac arrest (SCA) in athletes continues to grow, sports cardiologists are often asked to engage beyond the clinic by helping shape policies related to cardiovascular (CV) screening, emergency preparedness, and access to life-saving interventions.
- AI-Enabled Clinician: Chronic Cardiovascular Care in the Digital AgeIn this episode, Dr. Ami Bhatt speaks with Dr. Leslie Davis about how digital health tools are empowering patients to get ahead of symptom progression and helping underserved communities adopt at-home care.
- ACC Comments on 2027 Hospital OPPS and ASC Proposed RuleThe ACC submitted formal comments to the Centers for Medicare and Medicaid Services (CMS) on the 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed rule on Aug. 25.
- LCZ in nHCM: Sacubitril/Valsartan Promotes Cardiac Remodeling, But Not Functional Capacity, in Nonobstructive HCMFunctional capacity as measured by peak oxygen uptake (pVO2) was not improved with sacubitril/valsartan (LCZ696) in patients with nonobstructive hypertrophic cardiomyopathy (nHCM), while there was favorable cardiac structural remodeling, according to research published Aug. 19 in JACC: Heart Failure.



